Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Platinum-resistant Ovarian Cancer”

237 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 237 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03113487
What this trial is testing

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Platinum-Resistant Fallopian Tube CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Platinum-Resistant Primary Peritoneal Carcinoma
City of Hope Medical Center 29
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06509971
What this trial is testing

QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
West China Second University Hospital 39
Early research (Phase 1)Ended earlyNCT03608618
What this trial is testing

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Who this might be right for
Peritoneal MesotheliomaFallopian Tube AdenocarcinomaAdenocarcinoma of the Ovary+1 more
MaxCyte, Inc. 14
Testing effectiveness (Phase 2)Study completedNCT03268382
What this trial is testing

P53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Who this might be right for
High-grade Serous Ovarian Cancer
Aprea Therapeutics 36
Early research (Phase 1)Study completedNCT03639246
What this trial is testing

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Aravive, Inc. 53
Large-scale testing (Phase 3)WithdrawnNCT03632798
What this trial is testing

Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer

Who this might be right for
Recurrent Ovarian Cancer
Cordgenics, LLC
Testing effectiveness (Phase 2)Study completedNCT03206047
What this trial is testing

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+3 more
National Cancer Institute (NCI) 12
Large-scale testing (Phase 3)UnknownNCT05145218
What this trial is testing

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

Who this might be right for
Recurrent Platinum-resistant Ovarian Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 405
Testing effectiveness (Phase 2)Study completedNCT02591095
What this trial is testing

ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant or Refractory Ovarian Cancer
Centre Francois Baclesse 47
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07273396
What this trial is testing

Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian NeoplasmsPeritoneal Neoplasms
Seoul National University Hospital 53
Early research (Phase 1)Active Not RecruitingNCT03907527
What this trial is testing

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+31 more
Precigen, Inc 71
Testing effectiveness (Phase 2)Study completedNCT02431559
What this trial is testing

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
Ludwig Institute for Cancer Research 53
Testing effectiveness (Phase 2)UnknownNCT01100372
What this trial is testing

Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Medical University Innsbruck 154
Testing effectiveness (Phase 2)UnknownNCT03363867
What this trial is testing

BEACON - ABC in Recurrent Platinum Resistant HGSOC

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Peter MacCallum Cancer Centre, Australia 30
Early research (Phase 1)Looking for participantsNCT06305299
What this trial is testing

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Who this might be right for
Ovary NeoplasmOvarian CancerEpithelial Ovarian Cancer+1 more
UNC Lineberger Comprehensive Cancer Center 27
Large-scale testing (Phase 3)Study completedNCT04908787
What this trial is testing

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. 421
Large-scale testing (Phase 3)Active Not RecruitingNCT05116189
What this trial is testing

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

Who this might be right for
Ovarian CancerCarcinoma, Ovarian EpithelialFallopian Tube Neoplasms
Merck Sharp & Dohme LLC 643
Testing effectiveness (Phase 2)Study completedNCT02312245
What this trial is testing

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Mayo Clinic 13
Testing effectiveness (Phase 2)Study completedNCT03776812
What this trial is testing

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Recurrent Ovarian CancerRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma
Corcept Therapeutics 178
Testing effectiveness (Phase 2)Ended earlyNCT00023907
What this trial is testing

Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Load More Results